Behold the Dangers of a One-Trick Pony: Affymax, Inc. (AFFY) and More

Page 1 of 2

At the end of last year, I proclaimed Omontys — an erythropoiesis-stimulating agent, or ESA, that aids in the formation of red blood cells — as one of my 10 drugs approved by the Food and Drug Administration in 2012 to be thankful for. The drug, developed by Affymax, Inc.(NASDAQ:AFFY) and Takeda Pharmaceutical Company Limited, was designed to be a once-a-month injectable treatment for patients on dialysis with chronic kidney disease. Today, it’s the straw that broke Affymax shareholders’ back.

Affymax, Inc. (NASDAQ:AFFY)On Saturday, Affymax and Takeda, in cooperation with the FDA, announced the voluntary recall of all lots of injectable Omontys. According to the release, more than 25,000 patients have received the anemia drug since it launched, with 0.2% of them responding with a hypersensitivity reaction that — in a third of those patients — led to anaphylaxis. Fatal reactions were reported in 0.02% of all cases where Omontys was administered.

Houston, we have a problem.

For Takeda, the blow isn’t as severe, as it’s a large pharmaceutical company with dozens of partnerships. For Affymax, this is a completely different story.

In its third-quarter results, released in November, Affymax noted Omontys sales of just $15 million — it wasn’t exactly selling like hotcakes to begin with — and noted at the time that the company wouldn’t be receiving any further milestone or profit equalization payments from Takeda for 2012. Moving forward, it’s not going to be receiving anything as Omontys is Affymax’s only approved drug. Keep in mind that operating expenses including stock-based compensation were guided to a whopping $130 million to $135 million last quarter, and it boasts just $100 million in cash and investments.

OK… breathe… Affymax had to have thought this through and clearly has other compounds in its pipeline, right? That’d be wishful thinking because it only has two other compounds in clinical trials: a late-stage conversion study on — you guessed it — Omontys for use as a once-a-week ESA as opposed to three times a week, and a mid-stage study outside of the U.S. utilizing Omontys to treat dialysis and non-dialysis related anemia for patients with pure red cell aplasia.

(Bangs head on table)

It gets even worse. Let’s assume for a moment that Affymax and Takeda are able to work out these not-so-minor kinks with Omontys to the FDA’s satisfaction — it’ll still be giving Amgen, Inc. (NASDAQ:AMGN) even more time to further its market share lead. Amgen, which makes Epogen — the leading anemia treatment for the past two decades – fortified its market-leading spot a while ago by signing multi-year dialysis center agreements with DaVita HealthCare Partners Inc (NYSE:DVA) and Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS). They’re arguably the two biggest names in dialysis, as my Foolish colleague Brandy Betz noted last month. While this doesn’t negate Affymax from dealing with DaVita and Fresenius, it makes orchestrating an agreement far less likely.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!